Advertisement

Pharmaceutical Chemistry Journal

, Volume 47, Issue 11, pp 577–580 | Cite as

Effects of Melaxen and Valdoxan on Superoxide Dismutase and Catalase Activities in Experimental Hyperthyroidism

  • M. V. Gorbenko
  • T. N. Popova
  • K. K. Shul’gin
  • S. S. Popov
Article

The effects of Melaxen and Valdoxan on measures of biochemiluminescence (BCL) were studied on the background of the development of experimental hyperthyroidism in terms of the light sum of chemiluminescence (S) and the maximum peak intensity (I max), which characterize the intensity of free radical processes, and the tangent of the kinetic curve slope (tgα2), which reflects total antioxidant activity; effects on superoxide dismutase and catalase activities in tissues and serum were also studied. Increases in these measures due to oxidative stress in experimental hyperthyroidism were found to normalize in response to these agents.

Keywords

Hyperthyroidism free radical oxidation Melaxen Valdoxan superoxide dismutase catalase 

References

  1. 1.
    P. Venditti, M. Balestrieri, S. D. Meo, et al., J. Endocrinol., 155, 151–157 (1997).PubMedCrossRefGoogle Scholar
  2. 2.
    B. Pereira, R. Cosa, D. A. Safi, et al., J. Endocrinol., 140, 73–77 (1994).PubMedCrossRefGoogle Scholar
  3. 3.
    R. J. Reiter, D. X. Tan, C. Osuna, et al., J. Biomed. Sci., 7, 444–458 (2000).PubMedCrossRefGoogle Scholar
  4. 4.
    V. Srinivasan, Ph. D. R. Zakaria, Z. Othman, et al., J. Neuropsych. Clin. Neurosci., 24(3), 290–308 (2012).CrossRefGoogle Scholar
  5. 5.
    V. Fernandez, K. Simizu, S. B. M. Barros, et al., Endocrinology, 129(1), 85–91 (1991).PubMedCrossRefGoogle Scholar
  6. 6.
    E. I. Kuz’mina, A. S. Nelyubin, and M. K. Shchennikova, Interuniversity Collection: The Biochemistry and Biophysics of Microorganisms [in Russian], Gorky (1983), pp. 179–183.Google Scholar
  7. 7.
    M. A. Korolyuk, L. I. Ivanova, I. G. Maiorova, et al., Lab. Delo, No. 1, 16–19 (1988).Google Scholar
  8. 8.
    E. Lloyd and U. Lederman, Handbook of Applied Statistics [Russian translation], Moscow (1990).Google Scholar
  9. 9.
    E. J. Sanchez-Barcelo, C. M. Martinez-Campa, M. D. Mediavilla, et al., Rec. Patents Endocrine, Metabol. Immun. Drug Discov., 1(2), 142–151 (2007).CrossRefGoogle Scholar
  10. 10.
    O. A. Safonova, T. N. Popova, and L. Saidi, Vopr. Biol. Med. Farm. Khim., No. 7, 33–36 (2011).Google Scholar
  11. 11.
    O. Seymen, A. Seven, G. Candan, Acta Med. Okayma, 51(3), 129–133 (1997).Google Scholar
  12. 12.
    É. B. Arushanyan, Éksperim. Klin. Farmakol., 74(7), 41–45 (2011).Google Scholar
  13. 13.
    R. J. Reiter, D. X. Tan, L. C. Manchester, et al., Ann. N. Y. Acad. Sci., 959, 238–250 (2002).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • M. V. Gorbenko
    • 1
  • T. N. Popova
    • 1
  • K. K. Shul’gin
    • 1
  • S. S. Popov
    • 2
  1. 1.Voronezh State UniversityVoronezhRussia
  2. 2.N. N. Burdenko Voronezh State Medical AcademyVoronezhRussia

Personalised recommendations